Tag: biosimilars vs generics
Biosimilars are billed differently than generics under Medicare Part B. Each has its own HCPCS code and payment rate based on its ASP plus 6% of the reference product’s price. This system encourages biosimilar entry but doesn’t strongly incentivize switching. Learn how billing works and why adoption remains low in the U.S.
Medications
Archives
Recent-posts
Ecosprin (Aspirin) vs Top Alternatives: Full Comparison Guide
Oct, 26 2025
The Science Behind Iron-Folic Acid-Zinc and Cognitive Function
Sep, 4 2023
How the FDA Ensures Generic Drug Safety: A Look at Manufacturing Oversight
Apr, 30 2026
Generic vs Brand-Name Drugs: Key Differences Explained
Jan, 30 2026
Counterfeit Medication Red Flags: What to Watch For
Dec, 1 2025